ALT insider transaction filings
Altimmune, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-17. Screen ALT transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 4 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing by 1 insider — 15,000 shares, $44,250 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 5.
- Largest priced transaction: purchase of 15,000 shares @ $2.95 ($44,250) by Durso Jerome Benedict, filed 2026-08-13.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Durso Jerome Benedict — President and CEO, Director | 1 | 1 leg · 15,000 sh · $44,250 | — | — |
| Richardson Linda M — Chief Commercial Officer | 1 | — | — | 3 |
| Roberts M Scot — Chief Scientific Officer | 1 | — | — | 1 |
| WEAVER GREGORY L — Chief Financial Officer | 1 | — | — | 1 |
Recent Form 4 filings — Altimmune, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | Richardson Linda M — Chief Commercial Officer | Option exercise (M): 24,000 @ $0 · Tax withholding (F): 6,826 @ $3.24 · Option exercise (M): 24,000 (derivative) @ $0 | EDGAR |
| 2026-08-13 | 4 | Durso Jerome Benedict — President and CEO, Director | Purchase (P): 15,000 @ $2.95 | EDGAR |
| 2026-08-03 | 4 | Roberts M Scot — Chief Scientific Officer | Grant/award (A): 875 @ $2.41 | EDGAR |
| 2026-08-03 | 4 | WEAVER GREGORY L — Chief Financial Officer | Grant/award (A): 1,753 @ $2.41 | EDGAR |
| 2026-05-01 | 4 | Lawver Teri L — Director | Grant/award (A): 48,800 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Pisano Wayne — Director | Grant/award (A): 48,800 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Schafer Klaus — Director | Grant/award (A): 48,800 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Hodges Philip — Director | Grant/award (A): 48,800 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Sohn Catherine A. — Director | Grant/award (A): 48,800 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Jorkasky Diane — Director | Grant/award (A): 48,800 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | GILL JOHN — Director | Grant/award (A): 48,800 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | SAYARE MITCHEL — Director | Grant/award (A): 48,800 (derivative) @ $0 | EDGAR |
| 2026-04-06 | 4 | GILL JOHN — Director | Purchase (P): 9,200 @ $3.41 | EDGAR |
| 2026-04-01 | 4 | Durso Jerome Benedict — President and CEO, Director | Purchase (P): 15,000 @ $3.14 | EDGAR |
| 2026-04-01 | 4 | WEAVER GREGORY L — Chief Financial Officer | Purchase (P): 10,000 @ $3.15 | EDGAR |
| 2026-03-09 | 4 | Durso Jerome Benedict — President and CEO, Director | Purchase (P): 20,000 @ $3.54 | EDGAR |
| 2026-03-09 | 4 | WEAVER GREGORY L — Chief Financial Officer | Purchase (P): 5,000 @ $3.54 | EDGAR |
| 2026-02-27 | 4 | Roberts M Scot — Chief Scientific Officer | Grant/award (A): 222,670 (derivative) @ $0 · Grant/award (A): 95,430 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | WEAVER GREGORY L — Chief Financial Officer | Grant/award (A): 259,000 (derivative) @ $0 · Grant/award (A): 111,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Roberts M Scot — Chief Scientific Officer | Option exercise (M): 9,275 @ $0 · Tax withholding (F): 2,859 @ $5.60 · Grant/award (A): 5,567 @ $3.07 · Option exercise (M): 7,775 @ $0 · Tax withholding (F): 2,329 @ $5.55 · Option exercise (M): 9,275 (derivative) @ $0 · +1 more | EDGAR |
| 2026-02-02 | 4 | Jordt Raymond M — Chief Business Officer | Grant/award (A): 4,571 @ $3.07 | EDGAR |
| 2026-02-02 | 4 | Garg Vipin K — Director | Option exercise (M): 26,775 @ $0 · Tax withholding (F): 11,632 @ $5.60 · Grant/award (A): 6,926 @ $3.07 · Option exercise (M): 26,775 (derivative) @ $0 | EDGAR |
| 2026-01-29 | 4 | Jordt Raymond M — Chief Business Officer | Option exercise (M): 15,850 @ $0 · Tax withholding (F): 4,229 @ $6.18 · Option exercise (M): 15,850 (derivative) @ $0 | EDGAR |
| 2026-01-29 | 4 | Roberts M Scot — Chief Scientific Officer | Option exercise (M): 15,850 @ $0 · Tax withholding (F): 4,748 @ $6.18 · Option exercise (M): 15,850 (derivative) @ $0 | EDGAR |
| 2026-01-29 | 4 | Garg Vipin K — Director | Option exercise (M): 41,200 @ $0 · Tax withholding (F): 17,898 @ $6.18 · Option exercise (M): 41,200 (derivative) @ $0 | EDGAR |
| 2026-01-27 | 4 | Jordt Raymond M — Chief Business Officer | Option exercise (M): 14,600 @ $0 · Tax withholding (F): 3,855 @ $5.50 · Option exercise (M): 14,600 (derivative) @ $0 | EDGAR |
| 2026-01-27 | 4 | Roberts M Scot — Chief Scientific Officer | Option exercise (M): 14,600 @ $0 · Tax withholding (F): 4,373 @ $5.50 · Option exercise (M): 14,600 (derivative) @ $0 | EDGAR |
| 2026-01-27 | 4 | Garg Vipin K — Director | Option exercise (M): 42,050 @ $0 · Tax withholding (F): 17,984 @ $5.50 · Option exercise (M): 42,050 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | Pisano Wayne — Director | Purchase (P): 5,000 @ $4.08 | EDGAR |
| 2026-01-05 | 4 | Jordt Raymond M — Chief Business Officer | Option exercise (M): 9,375 @ $0 · Tax withholding (F): 2,475 @ $3.61 · Option exercise (M): 9,375 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Sohn Catherine A. — Director | Purchase (P): 500 @ $4.24 | EDGAR |
| 2025-12-29 | 4 | Jorkasky Diane — Director | Purchase (P): 527 @ $3.80 | EDGAR |
| 2025-12-23 | 4 | GILL JOHN — Director | Purchase (P): 12,500 @ $4.10 | EDGAR |
| 2025-12-22 | 4 | Durso Jerome Benedict — Director | Purchase (P): 12,500 @ $4.13 | EDGAR |
| 2025-12-01 | 4 | Durso Jerome Benedict — CEO-elect, Director | Grant/award (A): 1,824,400 (derivative) @ $0 · Grant/award (A): 633,700 (derivative) @ $0 | EDGAR |
| 2025-11-12 | 4 | WEAVER GREGORY L — Chief Financial Officer | Option exercise (M): 18,750 @ $0 · Tax withholding (F): 5,672 @ $4.28 · Option exercise (M): 18,750 (derivative) @ $0 | EDGAR |
| 2025-10-03 | 4 | Arbet-Engels Christophe — Chief Medical Officer | Grant/award (A): 450,000 (derivative) @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-10-03 | 4 | WEAVER GREGORY L — Chief Financial Officer | Grant/award (A): 166,800 (derivative) @ $0 · Grant/award (A): 57,900 (derivative) @ $0 | EDGAR |
| 2025-09-29 | 4 | Sohn Catherine A. — Director | Grant/award (A): 48,800 (derivative) @ $0 | EDGAR |
| 2025-09-29 | 4 | Durso Jerome Benedict — Director | Grant/award (A): 48,800 (derivative) @ $0 | EDGAR |
| 2025-09-29 | 4 | Lawver Teri L — Director | Grant/award (A): 48,800 (derivative) @ $0 | EDGAR |
| 2025-09-29 | 4 | Jorkasky Diane — Director | Grant/award (A): 48,800 (derivative) @ $0 | EDGAR |
| 2025-09-29 | 4 | GILL JOHN — Director | Gift (G): 2,714 @ $0 · Grant/award (A): 48,800 (derivative) @ $0 | EDGAR |
| 2025-09-29 | 4 | Schafer Klaus — Director | Grant/award (A): 48,800 (derivative) @ $0 | EDGAR |
| 2025-09-29 | 4 | Hodges Philip — Director | Grant/award (A): 48,800 (derivative) @ $0 | EDGAR |
| 2025-09-29 | 4 | Pisano Wayne — Director | Grant/award (A): 48,800 (derivative) @ $0 | EDGAR |
| 2025-09-29 | 4 | SAYARE MITCHEL — Director | Grant/award (A): 48,800 (derivative) @ $0 | EDGAR |
| 2025-09-17 | 4 | Richardson Linda M — Chief Commercial Officer | Grant/award (A): 278,000 (derivative) @ $0 · Grant/award (A): 96,000 (derivative) @ $0 | EDGAR |
| 2025-08-04 | 4 | Harris Matthew Scott — Chief Medical Officer | Grant/award (A): 2,018 @ $3.14 | EDGAR |
| 2025-08-04 | 4 | Roberts M Scot — Chief Scientific Officer | Grant/award (A): 846 @ $3.14 | EDGAR |
Recent 8-K events — Altimmune, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-28 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-16 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-16 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-03 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-01-28 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-19 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ALT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →